Retatrutide vs Testosterone for weight loss
Short answer: For weight loss, users rate them about the same: 91% report improvement with Retatrutide (222 reports) and 93% with Testosterone (45 reports).
Retatrutide has 22 meta-analyses and 6 randomized trials on PubMed; Testosterone has 75 and 125.
Based on 446 reports about Retatrutide and 822 about Testosterone. Not medical advice.
| Retatrutide Peptide | Testosterone Medication | |
|---|---|---|
| User score | 71 | 54 |
| Verdict | Mostly positive | Mostly positive |
| Positive of reports that state an outcome | 76% | 77% |
| Reports | 446 | 822 |
| Research | BResearch: Moderate | AResearch: Strong |
| Meta-analyses / RCTs | 22 / 6 | 75 / 125 |
| Mainly used for | ||
| Weight loss % reporting improvement | 91% (222) | 93% (45) |
| Appetite % reporting improvement | 73% (84) | — |
| Focus % reporting improvement | 83% (6) | 82% (28) |
| Energy % reporting improvement | 69% (75) | 92% (76) |
| Sleep % reporting improvement | 31% (26) | 79% (19) |
| Anxiety % reporting improvement | 40% (5) | 80% (25) |
| Mood % reporting improvement | 66% (32) | 88% (104) |
| Memory % reporting improvement | — | 100% (2) |
| Performance % reporting improvement | 82% (33) | 97% (149) |
| Recovery % reporting improvement | 100% (8) | 91% (23) |
| Pain & inflammation % reporting improvement | 78% (9) | 67% (6) |
| Digestion % reporting improvement | 46% (13) | — |
| Libido % reporting improvement | 25% (12) | 93% (70) |
| Hormones % reporting improvement | 100% (13) | 90% (91) |
| Blood sugar % reporting improvement | 75% (4) | — |
| Heart & lipids % reporting improvement | 37% (19) | 62% (8) |
| Skin & hair % reporting improvement | — | 40% (5) |
| Longevity % reporting improvement | — | 50% (2) |
| Common side effects | nausea, fatigue, stomach issues, insomnia | suppression, hair loss, acne, water retention |
| Typical dose reported | Not listed | 200 mg / weekly |
This systematic review identifies the state and mechanism of action of emerging pharmacotherapies undergoing or having completed phase 2 and phase 3 clinical trials. The information provided herein furthers the understanding of obesity management, implying direct clinical implications and stimulating research initiatives.
Pharmacol Rev, 2025 ↗“Drastically reduced appetite: At 5mg, I experienced near-total suppression of hunger and cravings. Steady, effortless fat loss: I didn't have to track macros obsessively or do extreme cardio.”
The guidelines also provide recommendations regarding identification of patients, dosing, monitoring, and follow-up. This Practice Pearl will discuss evidence-based testosterone therapy for management of HSDD in postmenopausal women.
Menopause, 2023 ↗“Feel the best I've ever felt in my life. TRT and peptides have been game changers for me!”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate